Source: https://www.iplitigationcurrent.com/2018/02/27/pleading-a-claim-for-misappropriation-of-trade-secrets-in-california-a-problem-of-particularity/
Timestamp: 2019-04-20 07:06:22+00:00

Document:
Recent decisions in California raised the question of whether a party asserting a claim for misappropriation of trade secrets must, in its pleadings, define the trade secrets at issue with particularity. The cases variously involved claims of misappropriation under both federal and state law: the Defend Trade Secrets Act (DTSA) and the California Uniform Trade Secrets Act (CUTSA). While pleading standards in federal court typically require only that the party set forth sufficient “facts to state a claim to relief that is plausible on its face,” there has been some disagreement among decisions in California for claims under the CUTSA.
More recent decisions, however, have rejected this “reasonable particularity” standard and reaffirmed that the correct pleading standard is simply the one articulated by the Supreme Court in Twombley and Iqbal. The court in Physician’s Surrogacy, Inc., for example, addressed the issue of pleading standards for a claim under the DTSA and held that a party is not required to define the trade secrets at issue with particularity at the pleading stage. Specifically the court found that “the Court applies general pleading standards, which require plausibility as opposed to particularity. In other words, the Court finds unpersuasive Defendants’ argument that Plaintiff must plead DTSA claims with particularity.” This finding is consistent with Supreme Court and Ninth Circuit precedent and numerous district court decisions.
Trade secret claims are typically governed by the notice pleading requirements of Rule 8(a). Only where the improper means used to misappropriate the trade secrets are specifically alleged to be “fraudulent” would the heightened “particularity” pleading standard articulated in Fed. R. Civ. P. 9(b) apply.
The court in Space Data Corp. specifically addressed claims under the CUTSA. The defendant argued that Plaintiff’s disclosure of trade secrets was deficient under California Code of Civil Procedure § 2019.210, which requires a party alleging misappropriation to identify the trade secret with reasonable particularity. The court, however, found that the trade secrets only needed to satisfy the Fed. R. Civ. P. 8 standard, and provide “reasonable” detail, which is enough to permit the defendant to prepare a defense and for the court to craft limits on discovery. A number of earlier decisions from the Northern District of California seemed to support defendant’s view. The court, however, noted that compliance with § 2019.210 is a separate issue from pleading standards on a motion to dismiss and does not apply to pleading requirements. Thus, the court held that claims under the CUTSA do not require a plaintiff to define the trade secrets at issue with reasonable particularity in its pleadings.
Furthermore, some district court cases have found that application of Section 2019.210 would violate the Erie Doctrine. According to the Erie Doctrine, when questions of state law are raised in federal court, the federal court generally applies the state’s substantive law but federal procedural law. The determination of whether a rule is “substantive” depends on the legal context and requires the court to consider whether the state rule conflicts with any applicable federal rule. In Hilderman v. Enea TekSci, Inc., the Southern District of California found that § 2019.210 conflicts with Fed. R. Civ. P. 26. As noted by Hilderman, Rule 26 sets forth required initial disclosures, permits discovery of “any nonprivileged matter that is relevant to any party’s claim or defense,” and provides for the opening of discovery, i.e., discovery shall not occur until the Rule 26(f) conference unless otherwise ordered by the Court or authorized under the Federal Rules of Civil Procedure. Section 2019.210, however, conditions discovery regarding trade secrets on plaintiff sufficiently identifying the trade secret. If Section 2019.210 is applied and the plaintiff fails to make an adequate disclosure by the Rule 26(f) conference, the plaintiff would be barred from engaging in discovery on his trade secret claims even though he would otherwise be permitted to do so under the Federal Rules. Accordingly, because the state court discovery rule conflicts with the Federal Rules, the Hilderman court held that that Section 2019.210 does not apply to federal actions. Other district courts in California have similarly found that Section 2019.210 has no applicability in federal court proceedings.
 See Physician’s Surrogacy, Inc. v. German, No. 17CV0718-MMA (WVG), 2017 WL 3622329 (S.D. Cal. Aug., 23, 2017); Space Data Corp. v. X, No. 16-cv-03260-BLF, 2017 WL 3007078 (N.D. Cal. July 14, 2017).
 Defend Trade Secrets Act of 2016, Pub. L. No. 114-153, 130 Stat. 376 (codified at 18 U.S.C. §§ 1831-39).
 Cal. Civ. Code §§ 3426.1-.11.
 Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570 (2007).
 877 F. Supp. 2d 983 (S.D. Cal. 2012).
 Id. at 988 quoting Diodes, Inc. v. Franzen, 260 Cal. App. 2d 244, 253 (1968).
 Physician’s Surrogacy, Inc., 2017 WL 3622329 at *9.
 Starr v. Baca, 652 F.3d 1202, 1216 (9th Cir. 2011).
 See, e.g., Premiere Innovations, Inc. v. IWAS Indus., LLC, 2007 WL 2873442, at *4 (S.D. Cal. Sept. 28, 2007); Aggreko, LLC v. Barreto, No. 1:16-cv-353, 2017 WL 963170, at *2 (D.N.D. Mar. 13, 2017) (applying Rule 8(a) and stating: “All that is required at this stage of the proceedings is an allegation that [Defendant] misappropriated [Plaintiff]’s trade secrets sufficient to put the defense on notice as to the nature of the claim.”).
 See Foam Supplies, Inc. v. The Dow Chem. Co., 2006 WL 2225392, at *14 (E.D. Mo. Aug. 2, 2006) (“[W]here a plaintiff alleges fraud as the improper means by which a party misappropriated trade secrets, Rule 9(b)’s particularity requirement applies.”).
 See Physician’s Surrogacy, Inc. v. German, 2017 WL 3622329, at *9 (S.D. Cal. Aug. 23, 2017) citing David Bohrer, Threatened Misappropriation of Trade Secrets: Making A Federal (DTSA) Case Out of It, 33 Santa Clara High Tech. L.J. 506, 521 (2017) (stating that the DTSA “does not incorporate the requirement . . . that . . . the plaintiff must identify its relevant trade secrets with ‘reasonable particularity’”); see also Chubb Ina Holdings Inc. v. Chang, No. 16-2354-BRM-DEA, 2017 WL 499682, at *10 (D.N.J. Feb. 7, 2017) (denying motion to dismiss and finding Plaintiffs “need not make out specific allegations as to exactly how Defendants used or disclosed Plaintiff[s’] trade secrets; there is no heightened pleading standard for a misappropriation claim, and Plaintiff[s are] entitled to seek discovery to support [their] allegations setting forth a prima facie claim.” quoting Osteotech, Inc. v. Biologic, 2008 WL 686318, at *5 (D.N.J. Mar. 7, 2008)); Sleekez, LLC v. Horton, CV 16–09–BLG–SPW–TJC, 2017 WL 1906957, at *6 (D. Mont. Apr. 21, 2017) (same).
 Space Data Corp., 2017 WL 3007078 at *3.
 Top Agent Network, Inc. v. Zillow, Inc., No. 14-cv-04769-RS, 2015 WL 7709655, at *4 (N.D. Cal. Apr. 13, 2015); Synopsys, Inc. v. ATopTech, Inc., No. C 13-CV-02965 SC, 2013 WL 5770542, at *5 n.1 (N.D. Cal. Oct. 24, 2013).
 Erie R. Co. v. Tompkins, 304 U.S. 64, 78 (1938).
 Hanna v. Plumer, 380 U.S. 460, 471 (1965).
 Hilderman v. Enea TekSci, Inc., No. 05cv1049 BTM (AJB), 2010 WL 143440, at *2 (S.D. Cal. 2010).
 United Westlabs, Inc. v. Seacoast Laboratory Data Systems, Inc., No. CV 08–8649–CJC (RNBx), 2009 WL 10675733, at *1 (C.D. Cal. Dec. 10, 2009) (“The Court finds that § 2019.210 likewise is a matter of state procedural law that has no applicability in a federal court proceeding.”); Funcat Leisure Craft, Inc. v. Johnson Outdoors, Inc., 2007 WL 273949 (E.D. Cal. Jan. 29, 2007) (holding that § 2019.210 does not apply to a federal action “unless stipulated otherwise or ordered after stipulation pursuant to case management orders, it is not within the discretion of the court to willy nilly apply bits and pieces of the discovery civil procedure codes of the various states, even the state in which the district court sits.”). But see Top Agent Network, Inc., 2015 WL 7709655, at *4; Synopsys, Inc., 2013 WL 5770542, at *5 n.1.

References: § 2019
 § 2019
 v. 
 § 2019
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 § 2019
 v. 
 § 2019